Literature DB >> 25698168

Role of membrane complement regulators in neuromyelitis optica.

Samira Saadoun1, Marios C Papadopoulos2.   

Abstract

BACKGROUND: It is unclear why AQP4-IgG primarily causes central nervous system lesions by activating complement, but generally spares peripheral AQP4-expressing organs.
OBJECTIVES: To determine whether peripheral AQP4-expressing cells are protected from complement-mediated damage by expressing complement regulators.
METHODS: Human tissue and cultured human cells were immunostained for aquaporin-4 (AQP4), CD46, CD55 and CD59. We also determined the vulnerability to AQP4-IgG and complement-mediated damage of astrocytes cultured alone or co-cultured with endothelial cells.
RESULTS: In normal brain, astrocyte end-feet express AQP4, but are devoid of CD46, CD55 and CD59. Immunoreactivity for CD46, CD55 and CD59 is not increased in or around neuromyelitis optica lesions. In kidney AQP4 is co-expressed with CD46 and CD55, in stomach AQP4 is co-expressed with CD46 and in skeletal muscle AQP4 is co-expressed with CD46. Astrocytes cultured alone co-express AQP4 and CD59 but, in astrocyte-endothelial co-cultures, AQP4 is found in cell processes devoid of CD59. Astrocytes co-cultured with endothelial cells are more vulnerable to AQP4-IgG and complement-mediated lysis than astrocytes cultured alone.
CONCLUSIONS: Complement regulators protect peripheral organs, but not the central nervous system, from AQP4-IgG and complement-mediated damage. Our findings may explain why neuromyelitis optica primarily damages the central nervous system, but spares peripheral organs.
© The Author(s), 2015.

Entities:  

Keywords:  AQP4; Devic’s syndrome; NMO-IgG; astrocytes; culture; endothelial cells; histology; human tissue

Mesh:

Substances:

Year:  2015        PMID: 25698168     DOI: 10.1177/1352458515571446

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  21 in total

Review 1.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 2.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

Review 3.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Ann N Y Acad Sci       Date:  2015-06-10       Impact factor: 5.691

Review 4.  Neuromyelitis optica spectrum disorders.

Authors:  Saif Huda; Dan Whittam; Maneesh Bhojak; Jayne Chamberlain; Carmel Noonan; Anu Jacob
Journal:  Clin Med (Lond)       Date:  2019-03       Impact factor: 2.659

Review 5.  Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.

Authors:  Jeffrey L Bennett; Gregory P Owens
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 6.  Applying complement therapeutics to rare diseases.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Despina Yancopoulou; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Clin Immunol       Date:  2015-09-01       Impact factor: 3.969

7.  Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder.

Authors:  Barbara Uzonyi; Zsóka Szabó; Eszter Trojnár; Satu Hyvärinen; Katalin Uray; Helle H Nielsen; Anna Erdei; T Sakari Jokiranta; Zoltán Prohászka; Zsolt Illes; Mihály Józsi
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

8.  Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G.

Authors:  Xiaoming Yao; Alan S Verkman
Journal:  Acta Neuropathol Commun       Date:  2017-07-27       Impact factor: 7.801

Review 9.  Update on biomarkers in neuromyelitis optica.

Authors:  Esther Melamed; Michael Levy; Patrick J Waters; Douglas Kazutoshi Sato; Jeffrey L Bennett; Gareth R John; Douglas C Hooper; Albert Saiz; Amit Bar-Or; Ho Jin Kim; Lakha Pandit; Maria Isabel Leite; Nasrin Asgari; Najib Kissani; Rogier Hintzen; Romain Marignier; Sven Jarius; John Marcelletti; Terry J Smith; Michael R Yeaman; May H Han; Orhan Aktas; Metha Apiwattanakul; Brenda Banwell; Denis Bichuetti; Simon Broadley; Philippe Cabre; Tanuja Chitnis; Jerome De Seze; Kazuo Fujihara; Benjamin Greenberg; Kerstin Hellwig; Raffaele Iorio; Sven Jarius; Eric Klawiter; Ingo Kleiter; Marco Lana-Peixoto; Kevin O'Connor; Jacqueline Palace; Friedman Paul; Naraporn Prayoonwiwat; Klemens Ruprecht; Olaf Stuve; Thomas Tedder; Silvia Tenembaum; Juan P Garrahan; Buenos Aires; Katja van Herle; Danielle van Pelt; Pablo Villoslada; Emmanuelle Waubant; Brian Weinshenker; Dean Wingerchuk; Jens Würfel; Scott Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23

10.  Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica.

Authors:  Stefania Rosito; Grazia Paola Nicchia; Claudia Palazzo; Anna Lia; Cinzia Buccoliero; Francesco Pisani; Maria Svelto; Maria Trojano; Antonio Frigeri
Journal:  J Cell Mol Med       Date:  2017-10-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.